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Arterial hypertension is a common, albeit modifiable risk fac-tor, for cardiovascular disease and mortality. Fortunately, 
there are several classes of antihypertensive therapies that alone 
or in combination are effective in lowering blood pressure. 
Reducing blood pressure limits organ damage and adverse car-
diovascular disease outcomes. Despite this antihypertensive 
armoury, new drugs that engage mechanisms of actions not har-
nessed by current compounds could provide valuable alternate 
first-line or complementary therapies to improve the treatment of 
high blood pressure. Such compounds that operate by a different 
mode of action also offer the theoretical prospect of treating the 
significant number of patients who are resistant to current thera-
pies,1–4 which represents a significant unmet clinical need.
Because obesity, diabetes mellitus, and increased age are 
major risk factors for hypertension and because the popula-
tion is living longer and becoming increasingly overweight, 
additional pharmacotherapies may prove valuable in treat-
ing the high blood pressure pandemic. Consistent with this 
need to improve the treatment of hypertension, pharmaceuti-
cal companies and academic researchers have programs to 
develop novel blood pressure–lowering drugs or interventional 
approaches, some involving devices, that can achieve this.5
PKG (protein kinase G) is well established as the end-
effector kinase in blood vessel dilation, facilitating blood pres-
sure lowering in response to agents that elevate NO. NO binds 
soluble guanylate cyclase, activating it to generate cyclic GMP 
that bind PKG to induce allosteric activation and then phos-
phorylation of many end-effector proteins that mediate vaso-
dilation. Oxidant-induced disulfide formation in PKG Iα is an 
alternate mechanism by which this kinase can be activated and 
contributes, at least in part, to the endothelium-derived hyper-
polarizing factor (EDHF) mechanism of vasodilation and blood 
pressure lowering. EDHF predominates over NO-cGMP– or 
prostacyclin-dependent mechanisms of vasodilation in resis-
tance blood vessel control of blood pressure,6–8 operating in 
various vascular beds in many species, including humans.9–11
Current blood pressure–lowering drugs do not use this 
mechanism. Because this oxidant-induced activation is a 
major mechanism of blood pressure lowering as described 
above, drugs that may recruit this pathway are anticipated to 
Abstract—Arterial hypertension continues to be a major health burden. Development of new antihypertensive drugs that 
engage vasodilatory mechanisms not harnessed by available therapies offer therapeutic potential. Oxidants induce an 
interprotein disulfide in PKG Iα (protein kinase G Iα) at C42, which is associated with its targeting and activation, resulting 
in vasodilation and blood pressure lowering. Consequently, we developed an assay and screened for electrophilic drugs 
that activate PKG Iα by selectively targeting C42, as such compounds have potential as novel antihypertensives with 
a mechanism of action that differs from current therapies. In this way, a drug that we termed G1 was identified, which 
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be effective vasodilators. As such, a compound, which would 
represent a unique drug class, stimulating a major endogenous 
mechanism responsible for blood pressure lowering in vivo, 
this may provide additional therapeutic strategies in addition 
to current treatment options. Furthermore, it is rational that 
this new class of drug may in theory perhaps also treat hyper-
tension that is resistant to current therapies, for which there is 
a significant unmet clinical need.
With the considerations above in mind, we set out to iden-
tify drugs that recruit the oxidative activation of PKG Iα. 
Our strategy of recruiting a major component of the blood 
pressure–lowering EDHF mechanism, by specifically target-
ing C42, which is unique to PKG Iα, is a rational approach 
that was anticipated to potentially yield a selective and highly 
effective drug. Our vision was that a drug capable of induc-
ing or mimicking the interprotein disulfide in PKG Iα would 
selectively react with C42 to target and activate the kinase, 
thus facilitate blood pressure lowering. Thus, we screened a 
library of electrophilic compounds, assessing their ability to 
induce oxidation of recombinant PKG Iα.
To do this, we developed an assay using recombinant PKG 
Iα and dibromobimane (dBBr), which fluoresces when it adducts 
vicinal thiols. Because the C42 residues on the adjacent parallel-
aligned chains of PKG Iα are vicinal, when dBBr is added to the 
kinase in the reduced state, it fluoresces (Figure 1A). However, 
if a drug induces oxidation of C42, this will attenuate the adduc-
tion of dBBr with the kinase and so reduce the fluorescence 
compared with vehicle-treated control (Figure 1A). Thus, if pre-
treatment of the kinase with a drug attenuates the fluorescence 
signal obtained when PKG Iα and dBBr are mixed, this would 
be consistent with C42 oxidation and therefore further investi-
gated. Having successfully identified such compounds, we then 
assessed their ability to induce vasodilation of isolated wild-type 
mesenteric arteries, with those that did so effectively undergoing 
a subsequent counterscreen. This counterscreen involved repeat-
ing the assessment of such compound to dilate the WT mesen-
teric preparation but concomitantly also assessing responses in 
mesenteries from C42S PKG Iα knockin (KI) mice. In this way, 
we identified a compound, named G1, which efficiently relaxes 
WT but not KI vessels, which was then assessed in a murine 
model of hypertension. G1 lowered blood pressure in hyperten-
sive WT, but not KI, mice in vivo. This provides proof of concept 
that drugs that activate PKG Iα by targeting C42 are a realistic 
strategy for generating novel antihypertensive medicines.
Methods
In Vitro Screen for Compounds That Induce 
Oxidation of PKG Iα
Molecules with potential electrophilic properties were obtained from 
InterBioScreen (http://www.interbioscreen.com/) and are individu-
ally listed in Table S1 in the online-only Data Supplement. In all 
assays, 1.1 µg/µL of recombinant PKG Iα (14–688; Merck Millipore) 
was reduced for 20 minutes at room temperature with 5 mmol/L 
TCEP. Reduced PKG Iα was then diluted to ≈1 µmol/L, based on the 
molecular weight of a monomer, in 100 mmol/L Tris-HCl pH 7.4 and 
750 ng placed into wells of a 96-well plate. In initial experiments, the 
fluorescence of dBBr (100 µmol/L) was compared between reduced 
PKG Iα and TCEP-only controls over a 1-hour period. In further 
experiments, dBBr fluorescence was compared between reduced and 
air oxidised PKG Iα (20 minutes at room temperature without TCEP) 
1 hour after the addition of 100 µmol/L dBBr. For the in vitro screen, 
750 ng of reduced PKG Iα was placed into each well of a 96-well plate 
preloaded with 100 µmol/L drug/well. After 10-minute incubation at 
room temperature, 100 µmol/L dBBr was added to each well. After a 
further 60-minute incubation at room temperature, dBBr fluorescence 
Figure 1. Overview of dibromobimane screening method and its validation. A, Schematic of the method used to identify drugs that target 
C42 of PKG Iα (protein kinase G Iα). As C42 on each of the chains of the kinase are vicinal to each other, this enables the bifunctional 
dibromobimane molecule to react with each residue, which results in it becoming fluorescent. Thus, dibromobimane provides readout 
of PKG Iα in the reduced state, and drugs that target C42 are anticipated to interfere with this and so lower the fluorescence signal 
compared with control. B, Validation studies showing combining dibromobimane with PKG Iα reduced with TCEP generates a time-
dependent increase above control preparations. C, Quantification of dibromobimane fluorescence signal generated by reduced versus 
oxidized PKG Iα. D, Screening and identification of compounds that may target PKG Iα C42 using a 96-well plate fluorimetric assay 
identified several compounds that markedly lowered the dibromobimane-dependent fluorescence signal compared with control. Several 
of these, as shown in Table, were subsequently tested for their ability to dilate mesenteric blood vessels.
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(λex 393 nm; λem 477 nm) in each well was assessed using a micro-
plate reader (SpectraMax GeminiXS; Molecular Devices).
Animal Studies
All procedures were performed in accordance with the Home Office 
Guidance on the Operation of the Animals (Scientific Procedures) 
Act 1986 in UK and were approved by an institutional review com-
mittee. Mice constitutively expressing PKG Iα Cys42Ser were gener-
ated on a pure C57BL/6 background by Taconic Artemis as described 
before.12 Age-matched and body weight–matched WT or PKG Iα 
Cys42Ser KI male mice were used in all studies. All animals had ad 
libitum access to standard chow and water. Mice were kept under spe-
cific pathogen-free conditions and under a 12-hour day/night cycle.
Myography
Second-order mesenteric arteries from WT or C42S PKG Iα KI 
mice were mounted in a Danish Myo Technology tension myograph, 
stretched to the optimal pretension condition with Danish Myo 
Technology normalization module and bathed in Krebs solution at 
37°C with a 95% O2:5% CO2 environment. Vasotone measurements 
were made after wake up with KCl (60 mmol/L) by determining the 
responses of U46619-contracted (0.1 μmol/L) mesenteric vessels to 
cumulatively increasing concentrations of test compounds. In some 
studies, vascular rings were isolated from the thoracic aorta; carotid, 
renal (second order), or femoral arteries were also studied.
Blood Pressure Measurements
Blood pressure and heart rate were assessed by radio telemetry in 
conscious freely moving mice as described before.12 Alzet osmotic 
mini-pumps were used to deliver angiotensin II at 1.1 mg/kg per day 
in some studies. Drug G1 was delivered intraperitoneally (3.7–14.8 
mg/kg) or orally (20 mg/kg) in some studies. To deliver G1 orally, 
without stress or risk of dislodging the telemetric probe catheter, it 
was provided suspended in water and set in gelatin flavored with 
sodium saccharin.
Assessing Vasodilator-Stimulated Phosphoprotein 
Phosphorylation
Rat aortic smooth muscle cells were maintained in Dulbecco modi-
fied eagle medium (GIBCO, Life Technologies) supplemented with 
10% fetal calf serum and 1% penicillin/streptomycin and kept at 
37°C in an incubator with 5% CO2. To assess VASP (vasodilator-
stimulated phosphoprotein) phosphorylation, smooth muscle cells 
grown on cell culture plates were exposed to varying concentrations 
of G1, 8-Br-cGMP (Sigma) or a combination of both. After 10-min-
ute incubation at 37°C, cells were lysed into sample buffer and then 
assessed for VASP Ser239 phosphorylation using Western immunob-
lotting (Cell Signaling).
Monitoring PKG Iα Disulfide Dimerization
Western immunoblotting was used to determine the redox state of 
PKG Iα as described previously,12 with maleimide (100 mmol/L) 
used in preparation buffers to alkylate thiols and prevent thiol disul-
fide exchange. Antibody ADIKAP-PK005 (Enzo Life Science) was 
used to probe blots for PKG Iα. Horseradish peroxidase–linked sec-
ondary antibody (Cell Signaling) and ECL reagent (GE Healthcare) 
were used. Digitized immunoblots were analyzed quantitatively with 
a Gel-Pro Analyzer 3.1. The amount of PKG Iα disulfide dimer in 
each sample was indexed by expressing the immunoblot signal at 
the dimeric weight as a percentage of the combined monomeric and 
dimeric signals.
Statistics
Differences between groups were assessed using ANOVA where 
appropriate, followed by Student t test when only 2 groups 
were tested or a Tukey test when ≥3 groups were compared. 
Differences were considered significant at the 95% confidence 
level (P<0.05).
Results
Figure 1A provides a schematic overview of the principle of 
the dBBr-screening assay that was used in combination with 
recombinant PKG Iα to identify candidate compounds that 
may induce oxidation of the kinase. C42 on adjacent chains 
of the PKG Iα homodimer is within a few Angstroms of each 
other13 and susceptible to oxidative disulfide conjugation.14 
dBBr is capable of reacting with each of the 2 C42 residues 
within the homodimer complex because of their proximity, 
with cross-linking inducing florescence. In perhaps the sim-
plest interpretation of this assay system, a drug that induced 
a disulfide between the kinase subunits would then prevent 
generation of a dBBr-dependent fluorescent signal as the 
requisite C42 thiols would no longer be available. Figure 1B 
shows that an assay mixture that contained recombinant PKG 
Iα and TCEP, which is included to maintain the kinase in the 
reduced state, generates a time-dependent signal over 60 min-
utes. When PKG Iα was selectively removed, dBBr failed to 
generate a signal above baseline, indicating that the signal gen-
erated was dependent on the presence of the kinase. Overall, 
this indicates that the dBBr assay was suitable for assaying the 
oxidation state of PKG Iα. Consistent with this, when PKG Iα 
in the reduced state was compared with oxidised kinase, there 
was a clear and reproducible difference in dBBr-dependent 
fluorescence observed at the 60-minute time point (Figure 1B).
Next, the compound library was tested in the dBBr assay 
system, which being in a 96-well plate format allowed the effi-
cient and rapid screening of ≈300 candidate compounds. The 
signal generated by reduced PKG Iα, because its C42 thiol 
groups are available to react efficiently with dBBr, is shown in 
red. Compounds of particular interest were those that substan-
tively attenuated dBBr-dependent fluorescence, as this was 
likely because they induced oxidation of C42. On this basis, 
12 compounds, whose chemical structures are shown in Table, 
were chosen for further study–as is the extent to which they 
prevented dBBr interaction with PKG Iα.
The 12 compounds were examined for their ability to relax 
isolated WT mesenteric artery preparations using wire myog-
raphy (Figure 1D). In this way, 5 compounds were identified 
for follow-up myography studies, repeating the assessment of 
their ability to relax WT mesenteries but concomitantly also 
investigating their comparative abilities to dilate vessels from 
the C42S PKG Iα KI mice (Figure 2B through 2F). All 5 com-
pounds again relaxed the WT preparations, so corroborating 
the previous observations, but only 1 of the compounds failed 
to induce efficient relaxation in mesenteries from the C42S 
PKG Iα KI (Table). Thus, compound STOCK1N-05437, 
which we subsequently refer to as drug G1, is effective at 
inducing vasodilation in WT but not KI preparations—consis-
tent with it activating PKG Iα by targeting C42.
Cinaciguat, which elevates cGMP to dilate blood vessels, 
dose dependently relaxed mesenteries from WT or KI to the 
same extent (Figure 3A). This comparable vasodilation to an 
agent that elevates cGMP, which is consistent with previous 
findings,12 contrasts the disparate responses of the 2 genotypes 
to G1. Vessels from KI mice are significantly deficient in their 
vasodilatory responses to G1 (Figure 3B), showing the impor-
tance of C42 in the mechanism of action of the compound. 
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The PKG inhibitor KT5823 attenuated G1-dependent vasodi-
lation in vessels from WT mice but also reduced the already 
impaired relaxation to the drug in mesenteries isolated from 
KIs (Figure 3B). G1 was also able to dilate vascular rings 
isolated from the thoracic aorta, as well as carotid, renal, and 
femoral arteries (Figure 3C).
The membrane-permeable cGMP mimetic 8-Br-cGMP, 
when applied to smooth muscle cells at 10 or 50 µmol/L, 
Table. Summary of Molecules Studied in Detail in This Study
Compound
% Decrease in dBBr 
Fluorescence Structure
WT Mesenteric 
Vessel Relaxation
C42S KI Mesenteric 
Vessel Relaxation
STOCK1N-03079
52.6 No …
STOCK1N-05437 
(drug G1) 93.7 Yes No
STOCK1N-06505
64.8 No …
STOCK1N-06594
71.6 No …
STOCK1N-07458
57. 9 Yes Yes
STOCK1N-09840
77.8 No …
STOCK1N-16139
55.9 No …
STOCK1N-16313
51.9 No …
STOCK1N-45544
77.3 Yes Yes
STOCK1N-46228
55.0 Yes Yes
STOCK1N-49242
65.9 Yes Yes
STOCK1N-54517
62.4 No …
Drug G1 was the only drug to induce oxidation of PKG Iα as well as induce vasodilation of WT, but not KI, mesenteries. dBBr 
indicates dibromobimane; KI, knockin; PKG Iα, protein kinase G Iα; and WT, wild type.
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induced a concentration-dependent increase in VASP phos-
phorylation. In contrast, when cells were exposed to G1 alone 
at 10 or 50 mmol/L, this did not alter VASP phosphorylation 
(Figure 3D). However, it was notable that when cells were 
concomitantly exposed to 10 mmol/L 8-Br-cGMP and G1, 
there was a synergistic effect, with phosphorylation of VASP 
being greater than that with 10 µmol/L 8-Br-cGMP alone. 
When 8-Br-cGMP was applied at 50 mmol/L, the increase 
in phospho-VASP was robust, perhaps representing maximal 
phosphorylation, which would explain why cotreatment with 
G1 did not potentiate the phosphorylation signal.
G1 was next tested in vivo in healthy mice implanted with 
telemetric devices that allow blood pressure and heart rate to 
be constantly monitored. G1 or vehicle control was admin-
istrated by intraperitoneal injection, and the acute impact on 
hemodynamics assessed. Drug G1 administered at 7.4 mg/
kg did not decrease blood pressure, but there was a concomi-
tant reflex tachycardia (Figure 4A and 4B). When this was 
repeated using 14.8 mg/kg dose of G1, again blood pressure 
was not altered—but this higher dose induced a potentiated 
increase in heart rate (not shown). These reflex tachycardia 
responses are anticipated in response to a drug that induces 
vasodilation.15 As the observations presented above relating to 
G1-induced tachycardia were promising, WT or KI mice were 
administered angiotensin II for 7 days using an osmotic mini-
pump to induce hypertension. On day 8 of this hypertension 
protocol, G1 (3.7 or 14.8 mg/kg) or vehicle was coadminis-
tered intraperitoneally. G1 induced a rapid, dose-dependent 
drop in mean arterial pressure in WT mice, which with the 
higher dose slowly recovered to basal during the ensuing ≈90 
minutes (Figure 4C and 4D). Aorta was isolated from mice 
exposed to angiotensin II and vehicle or 14.8 mg/kg G1 for 
≈20 minutes and assessed for the redox state of PKG Iα 
using Western immunoblotting, which showed that the drug 
had induced oxidation of the kinase to the interprotein disul-
fide state (Figure 4E). Intraperitoneally administered G1 was 
tested again using the angiotensin II hypertension model, but 
this time comparing the responses of WT to C42S PKG Iα 
KI mice. G1 efficiently lowered blood pressure in WT, but 
only partially in the KI (Figure 4F). However, it should be 
considered that in these initial experiments, the drug was 
administered intraperitoneally at a relatively high dose and so 
is anticipated to be more bioavailable than when the drug is 
provided orally, which was our ultimate goal.
In subsequent studies using the same angiotensin II–
induced hypertension model, G1 was next administered orally 
Figure 2. Screening candidate 
compounds for their ability to dilate 
mesenteric vessels by specifically 
targeting PKG Iα (protein kinase G Iα) 
C42. A, Twelve compounds that the 
fluorescence screen assay identified 
as likely targeting PKG Iα C42 were 
examined for their ability to dilate 
mesenteric arteries from wild-type mice, 
which 5 of them did efficiently. B–F, 
The 5 compounds that induced efficient 
vasorelaxation were assessed again, 
repeating the assessment of their ability 
to dilate vessels from wild-type mice, 
but at the same time comparing their 
ability to do this in mesenteries from 
C42S PKG Iα KI mice. As summarized in 
Table, a compound that we have called 
G1 efficiently dilated vessels from wild-
type but not those from the knockin mice. 
Drug G1 was considered a hit compound 
that we then assessed for its ability to 
lower blood pressure in vivo.
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at 20 mg/kg for 4 days after which it was removed with con-
tinued hemodynamic monitoring. Orally administered G1 
effectively lowered blood pressure in WT, whereas there was 
no blood pressure–lowering response in the KI or the treat-
ment groups administered vehicle (Figure 5A through 5C). 
G1 had no impact on the heart rate compared with vehicle 
in either genotype. When G1 was removed, the blood pres-
sure of the WT increased back to match those in the other 3 
experimental treatment groups, providing further reassurance 
that G1 shows characteristics that would be anticipated for an 
antihypertensive. It may appear that G1 demonstrates tachy-
phylaxis (Figure 5C), as mean arterial progressively increased 
during the 4 days when the drug was administered. However, 
it is important to note that G1 is coadministered with angio-
tensin II, which when given alone continued to increase blood 
pressure. In fact, the delta decrease in mean arterial pressure 
achieved by G1 in the presence of angiotensin II compared 
with the angiotensin II plus vehicle group was 8.5 mm Hg on 
day 1, 14.6 mm Hg on day 2, 19.6 mm Hg on day 3, and 14.1 
mm Hg on day 4.
Discussion
There are many current pharmacotherapies that are reasonably 
efficacious in the treatment of systemic arterial hypertension. 
These include renin–angiotensin–aldosterone system antago-
nists, diuretics, and β-blockers, which alone or in combina-
tion are effective in lowering blood pressure. However, despite 
the availability of these antihypertensive drugs, the develop-
ment of new pharmacotherapies with mechanisms of action 
that differ from current compounds may prove valuable in the 
treatment of high blood pressure. Such compounds may pro-
vide first-line therapies that complement those already used, 
but because of the disparate mode of action theoretically may 
also treat some patients with resistance to current therapies, 
for which there is an unmet clinical need.1–4
We identified a new mechanism by which PKG Iα can be 
activated by disulfide formation to relax blood vessels,14,16,17 
which is important in vivo.12 We hypothesized that drugs that 
bind PKG Iα to induce or mimic the disulfide may have thera-
peutic blood pressure–lowering actions. Because disulfide 
activation of PKG Iα contributes to an endogenous mecha-
nism of vasodilation,12,17 a drug that engages this mechanism 
may be especially efficacious in the context of blood pressure 
lowering. Furthermore, because the therapies that are cur-
rently used likely do not engage this disulfide-induced activa-
tion of PKG Iα mechanism of vasodilation, such compounds 
conceivably may work in scenarios where current therapies 
fail, such as resistant hypertension, as well as potentially pro-
viding an alternative or complementary approach to current 
treatments. Although nitroglycerin-dependent blood pres-
sure lowering is partly mediated by oxidation of PKG Iα,18 
this mechanism is likely a minor component as this drug also 
releases the potent vasodilator NO. Indeed, NO derived from 
nitroglycerin increases cGMP that binds to PKG Iα and lim-
its its oxidation,16,19 further limiting the disulfide-mediated 
activation mechanism. Apart from this, sustained administra-
tion of nitroglycerin results in the tolerance phenomenon,20 
whereby the drug stops working and so precludes its use for 
Figure 3. Drug G1-induced vasodilation involves cGMP-independent activation of PKG Iα (protein kinase G Iα) A, Cinaciguat induced 
comparable dose-dependent vasodilation in mesenteries isolated from wild-type (WT) or C42S PKG Iα knockin (KI) mice. B, G1-
dependent vasodilation of mesenteries from WT was attenuated by the PKG inhibitor KT5823, as was the partial relaxation caused by 
the compound in vessels from KI mice. C, G1 caused vasodilation in arteries isolated from several vascular beds, inducing more potent 
vasodilatory actions in the smaller vessels. D, 10 or 50 mmol/L 8-Br-cGMP induced phosphorylation of VASP (vasodilator-stimulated 
phosphoprotein) S239 in smooth muscle cells, whereas G1 did not. When 10 or 50 mmol/L G1 and 10 mmol/L 8-Br-cGMP were 
concomitantly administered to the cells, there was significant potentiation of the VASP phosphorylation signal generated compared with 
10 mmol/L 8-Br-cGMP alone.
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the chronic treatment of arterial hypertension. We only tested 
G1 for 4 days, during which it continued to lower blood pres-
sure in the angiotensin II–induced hypertension model. It will 
be important in subsequent studies evaluating G1 that lon-
ger therapy durations be examined to more fully rule out the 
possibility of tachyphylaxis as occurs with the nitroglycerin 
tolerance. Although it should be noted that when we studied 
nitroglycerin in mice, we found tolerance developed before 2 
days,18 whereas G1 continued to work at 4 days, which was 
the longest duration examined. Any future studies might also 
investigate whether G1, or indeed any optimized analogues, 
work as an antihypertensive in other models of hypertension.
With the considerations above in mind, we set out to iden-
tify compounds that induce the oxidative activation of PKG 
Iα, with subsequent studies to further assess candidates iden-
tified for their ability to dilate resistance blood vessels and 
lower blood pressure in vivo. Our vision was that drug-like 
molecules capable of inducing or mimicking disulfide of PKG 
Iα would have electrophilic properties. Consequently, we 
assembled a small chemical library (Table S1), deliberately 
selecting compounds with features that are anticipated to result 
in reactivity with thiolates. Such compounds with potential for 
protein conjugation are normally excluded from drug librar-
ies as they have been thought to have significant potential for 
nonselective, broad, and irreversible modification of proteins. 
This historical view of so-called covalent drugs that adduct 
proteins is changing, with the realization that such compounds 
may offer selectivity, potency, and pharmacodynamic advan-
tages over traditional drugs that bind targets reversibly.21–23 
Furthermore, it should be remembered that commonly used 
drugs such as aspirin, penicillin, and omeprazole mediate their 
actions via covalent adduction mechanisms.24
To avoid widespread modification of disparate thiols, an 
electrophilic drug is likely to have specific features that enable 
this. The thiol-reactive electrophilic moiety would likely have 
relatively low reactivity with cysteines to avoid rapid reaction 
with abundant protein or nonprotein thiols such as glutathi-
one. In this regard, despite its abundance, reduced glutathione 
Figure 4. Drug G1 lowers blood pressure in hypertensive but not normotensive wild-type (WT) mice. A and B, G1 administered at 7.4 
mg/kg to healthy WT mice did not alter their blood pressure but induces reflex tachycardia to increase heart rate. C and D, Mice were 
administered angiotensin II to increase their blood pressure, after which they were treated with 3.7 or 14.8 mg/kg G1 intraperitoneally, 
which decreased their blood pressure by 20.6±6.9 or 50.6±9.1 mm Hg, respectively. E, Aorta was isolated from mice exposed to 
angiotensin II and vehicle or angiotensin II and G1 and assessed for the redox state of PKG Iα (protein kinase G Iα). This showed that G1-
induced oxidation of PKG Iα to the disulfide state in vivo. F, G1 efficiently lowered blood pressure of angiotensin II–induced hypertensive 
WT, but not C42S PKG Iα knockin (KI), mice.
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is not a major issue because the high acid dissociation con-
stant (pKa) of its thiol renders it significantly unionized and 
so unreactive at physiological pH. Indeed, the same is true 
for the majority of protein thiols, with a key strategy in the 
design of covalent inhibitors being the targeting of a specific 
low pKa nucleophilic cysteine thiol that are absent or rare in 
related proteins, so limiting off-target effects in family mem-
bers.21 An issue with limiting the electrophilicity and so reac-
tivity of a drug is that it will not typically associate with a 
target protein with reactive ionised thiol (termed a thiolate) 
for sufficiently long to allow a reaction and so conjugation 
to occur. This may be overcome during the design of a cova-
lent drug by including additional chemical features, in addi-
tion to its electrophilicity, that enable the drug to first bind 
to a target protein—directing it to the protein with the target 
thiolate. This increases the residence time of the drug with 
the target, allowing sufficient time for the conjugative addition 
reaction to occur. Once the covalent adduction occurs, it may 
be irreversible or only removed slowly, potentially resulting 
in high potency and advantageous pharmacodynamics.21–23 In 
this connection, it is notable that G1 contains an indole ring 
that resembles the purine ring in authentic cGMP. Even partial 
affinity of G1 for PKG may afford selectivity by allowing the 
drug and kinase to associate, providing the opportunity when 
is debinds for it to interact with C42 to afford oxidative activa-
tion. As other isoforms of PKG lack C42, meaning G1 cannot 
react with those kinases even if they transiently interact. Thus, 
this 2-component mechanism in which a selectivity filter is 
combined with soft electrophile reaction chemistry manifests 
as a potent and selective hit compound. This likely explains 
the ability of G1 to efficiently lower the blood pressure of WT, 
but not C42S PKG Iα KI, mice that are hypertensive. Although 
G1 lowered blood pressure in hypertensive animals, it failed 
to in those that were healthy and normotensive. However, G1 
did increase heart rate in those mice, which is consistent with 
the anticipated reflex tachycardia in response to acute treat-
ment with vasodilator pharmacotherapy.15
Attempts have been made to generate antihypertensives 
through the development of drugs that inhibit phosphodies-
terase 5, with the anticipation that it would elevate cGMP 
and activate PKG to lower blood pressure. It is notable that 
despite the successful generation of such inhibitors, that they 
are rather ineffective systemic arterial vasodilators and are not 
used as antihypertensives.25,26 NO-cGMP also has complex 
direct effects on myocardial function with overstimulation 
of this pathway being negatively inotropic,27,28 with dysregu-
lated excitation–contraction coupling perhaps contributing to 
diastolic dysfunction.29 In this connection, it is notable that 
phospholamban S16 is selectively phosphorylated by disulfide 
PKG Iα, to directly regulate and enhance myocardial relax-
ation during diastole.30 An implication is that G1 may offer a 
therapy against diastolic dysfunction, which warrants further 
exploration. Phosphodiesterase 5 inhibition, which can elevate 
cGMP, has, however, proven unsuccessful in the treatment of 
heart failure with preserved ejection fraction,31 whereas this 
pharmacotherapy protected against cardiac injury after trans-
verse aortic constriction32 or doxorubicin chemotherapy.33
Although phosphodiesterase 5 inhibitors have proven 
rather ineffective in therapy of systemic arterial hypertension, 
such compounds are effective in vasodilating blood vessels 
Figure 5. Oral drug G1 functions as an effective antihypertensive by targeting C42 of PKG Iα (protein kinase G Iα). A–D, Hypertension 
was induced in wild-type (WT) or knockin (KI) mice with angiotensin II. Each genotype was then administered vehicle or G1 (20 mg/kg 
per day) orally for 4 d in the continued presence of angiotensin II. It was evident that orally supplied G1, but not vehicle, was effective at 
lowering mean arterial pressure (MAP), systolic pressure (SP), and end-diastolic pressure (DP) in WT, but not KI, mice. Heart rate did not 
differ between genotype or drug treatment groups.
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from the pulmonary or penile circulation34,35 and consequently 
are effective in the treatment of pulmonary hypertension or 
erectile dysfunction. These observations are in line with the 
NO-cGMP pathway not being a major mediator of blood pres-
sure, consistent with studies showing that EDHF mechanisms 
are likely more important in this regard.6–11 This is intriguing 
as clearly the NO-cGMP pathway can be recruited in the arte-
rial system to lower blood pressure, as coadministration of the 
NO donor nitroglycerin with a phosphodiesterase 5 inhibitor 
lowers blood pressure substantively to induce hypotension, 
such that this dual treatment is clinically contraindicated.25,26 
It would appear that while the systemic arterial system is 
equipped with the component enzymes of the NO-cGMP-
PKG pathway, that this is not a major mechanism of endog-
enously controlled vasodilation. Perhaps, the most likely 
explanation for this is that the systemic resistance arteries do 
not generate NO, but instead, their NO synthase enzymes are 
uncoupled and so generate oxidants.11 These oxidants medi-
ate, at least in part, the EDHF-dependent vasodilation that 
predominates in such resistance vessel. The drug G1 we have 
identified recruits the oxidative activation of PKG Iα to lower 
blood pressure and, as such, harnesses the major mechanism 
of endogenous systemic arterial vasodilation. Thus, although 
drugs that elevate cGMP have not proven effective as antihy-
pertensives, compounds such as G1 that engage the oxidative 
activation PKG Iα may be more successful.
PKG Iα is activated by cGMP or oxidants, and both of 
these agents induce vasorelaxation, and so it is perhaps logi-
cal to assume that this dilatory outcome is mediated by the 
phosphorylation of the same substrates. This is not neces-
sarily the case. The interprotein C42 disulfide in PKG Iα 
occurs within the substrate-targeting domain,36 and this may 
cause disparate targeting compared with cGMP. Vasodilation 
induced by oxidants is deficient in the C42S PKG KI mouse, 
whereas NO-induced or 8-Br-cGMP–induced vasodilation is 
identical in both genotypes.12 Essentially, the mechanism of 
oxidant-dependent versus NO-cGMP–dependent vasodila-
tion is different, despite PKG Iα being involved in both of 
them. Consistent with this, although G1-dependent vasodi-
lation was deficient in KI mesenteries compared with WT, 
there was no difference between genotypes in vasorelax-
ation to the cGMP-elevating agent cinaciguat in the studies 
reported here. 8-Br-cGMP stimulated VASP phosphorylation 
in smooth muscle cells, whereas administration of G1 alone 
did not do this. However, it was evident that G1 synergized 
with 8-Br-cGMP to potentiate VASP phosphorylation. It is 
possible that G1-induced oxidation of PKG Iα targets it to 
its substrates, with the 8-Br-cGMP stimulating activity of the 
kinase. Such a mechanism would be consistent with poten-
tiated phosphorylation of VASP observed when both com-
pounds were coadministered.
It is evident that G1 can have some off-target effects inde-
pendently from C42 PKG Iα, as mesenteries isolated from 
C42S PKG Iα KI mice relaxed when higher concentrations 
of the compound were used. Furthermore, G1 administered 
by intraperitoneal injection partially reduced the blood pres-
sure of hypertensive KI mice, although markedly less so 
than in hypertensive WTs. We conclude that G1 can couple 
to vasodilation and blood pressure lowering by a C42 PKG 
Iα-independent mechanism. However, it is important to high-
light that when the drug was administered orally at 20 mg/
kg to hypertensive mice, the compound only lowered blood 
pressure in WT but not KI. Because drugs are used at progres-
sively higher concentrations, they will bind increasingly more 
targets and may affect the function of some of them—gener-
ating off-target effects. This may be because G1 is bioavail-
able at a higher concentration with intraperitoneal injection, 
whereas with oral administration, the drug likely does not 
reach the same tissue concentration, perhaps because of first-
pass metabolism and inefficiencies in absorption.
Perspectives
In summary, we have provided proof-of-principle that oxidant-
induced activation of PKG Iα can be harnessed as a pharma-
cotherapy for the treatment of hypertension. Indeed, we have 
identified a hit compound, which we have called G1, which 
was able to efficiently lower blood pressure in hypertensive 
WT mice. Its inability to lower blood pressure in hypertensive 
C42S PKG Iα KI mice provides robust evidence for target val-
idation. KI mouse only differs from PKG Iα in the WT mouse 
by a single atom,12 meaning that we can confidently ascribe 
the action of G1 to its interaction with C42 of the kinase. This 
hit compound could be developed into a lead, with the pros-
pect of enhancing its potency and other desired attributes of 
a novel antihypertensive drug. Such improved variants of G1 
could be examined more extensively in terms of their ability 
to lower blood pressure in a variety of models of hypertension 
in multiple species, perhaps including humans.
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What Is New?
•	We have provided proof-of-principle for a new class of antihypertensive 
drugs.
•	 The hit compound we have identified induces vasodilation and blood pres-
sure lowering via the oxidative activation of PKG Iα (protein kinase G Iα).
What Is Relevant?
•	These observations are relevant in vivo as C42S PKG Iα knockin mice, 
which express an engineered form of the kinase that cannot be activated 
by oxidants, were resistant to the compound we have identified.
•	The hit compound we have identified harnesses an endogenous vasodi-
latory mechanism not used by current pharmacotherapies and as such 
may provide an effective complementary strategy for combating high 
blood pressure or perhaps resistant hypertension.
Summary
The oxidative activation of PKG Iα is a significant endogenous 
mechanism of vasodilation and blood pressure-lowering that is 
not harnessed by current antihypertensive pharmacotherapies. We 
have identified a hit compound that recruits this mechanism and it 
has proved efficient in lowering blood pressure in vivo in a model of 
murine hypertension. Our observations provide proof-of-principle 
for a new class of antihypertensive drugs that have potential for 
further development for clinical use in humans.
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Table S1
Molecules from Interbioscreen used in this study
Index Molecules were obtained from Interbioscreen 
1 STOCK1N‐03030 DNC (http://www.interbioscreen.com)
2 STOCK1N‐19321 DNC
3 STOCK1N‐51902 DNC GNC Rare derivatives
4 STOCK1N‐06800 DNC DNC
5 STOCK1N‐31035 RAR RAR
6 STOCK1N‐08486 RAR
7 STOCK1N‐05758 RAR highlighted molecules indicate those investigated
8 STOCK1N‐07458 RAR  in greater detail in this study
9 STOCK1N‐03196 RAR
10 STOCK1N‐57611 RAR
11 STOCK1N‐31011 DNC
12 STOCK1N‐73661 DNC
13 STOCK1N‐08621 RAR
14 STOCK1N‐06310 DNC
15 STOCK1N‐06691 RAR
16 STOCK1N‐04694 RAR
17 STOCK1N‐11714 RAR
18 STOCK1N‐03735 RAR
19 STOCK1N‐55511 DNC
20 STOCK1N‐16313 RAR
21 STOCK1N‐06029 DNC
22 STOCK1N‐54912 DNC
23 STOCK1N‐57526 DNC
24 STOCK1N‐58013 DNC
25 STOCK1N‐05620 DNC
26 STOCK1N‐56155 DNC
27 STOCK1N‐24711 DNC
28 STOCK1N‐71851 GNC
29 STOCK1N‐49547 GNC
30 STOCK1N‐09101 GNC
31 STOCK1N‐54517 GNC
32 STOCK1N‐09726 RAR
33 STOCK1N‐46228 DNC
34 STOCK1N‐44427 GNC
35 STOCK1N‐16691 DNC
36 STOCK1N‐13224 DNC
37 STOCK1N‐06594 DNC
38 STOCK1N‐09840 DNC
39 STOCK1N‐24416 DNC
40 STOCK1N‐01339 DNC
41 STOCK1N‐01103 DNC
42 STOCK1N‐14204 DNC
43 STOCK1N‐12472 DNC
44 STOCK1N‐03079 RAR
45 STOCK1N‐11306 DNC
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46 STOCK1N‐43894 DNC
47 STOCK1N‐45388 DNC
48 STOCK1N‐05887 DNC
49 STOCK1N‐05728 DNC
50 STOCK1N‐06289 DNC
51 STOCK1N‐11489 DNC
52 STOCK1N‐51795 DNC
53 STOCK1N‐04305 DNC
54 STOCK1N‐03280 DNC
55 STOCK1N‐11383 DNC
56 STOCK1N‐11268 DNC
57 STOCK1N‐03166 DNC
58 STOCK1N‐57050 RAR
59 STOCK1N‐57713 RAR
60 STOCK1N‐30541 RAR
61 STOCK1N‐73226 DNC
62 STOCK1N‐18635 DNC
63 STOCK1N‐07999 RAR
64 STOCK1N‐10126 DNC
65 STOCK1N‐06505 DNC
66 STOCK1N‐67880 GNC
67 STOCK1N‐02870 DNC
68 STOCK1N‐57870 DNC
69 STOCK1N‐28013 DNC
70 STOCK1N‐24598 DNC
71 STOCK1N‐44554 DNC
72 STOCK1N‐06387 DNC
73 STOCK1N‐05437 RAR
74 STOCK1N‐08900 RAR
75 STOCK1N‐06813 RAR
76 STOCK1N‐00851 RAR
77 STOCK1N‐06530 RAR
78 STOCK1N‐04678 DNC
79 STOCK1N‐09835 RAR
80 STOCK1N‐07034 RAR
81 STOCK1N‐57116 RAR
82 STOCK1N‐23279 DNC
83 STOCK1N‐52322 GNC
84 STOCK1N‐27040 DNC
85 STOCK1N‐30214 DNC
86 STOCK1N‐46720 RAR
87 STOCK1N‐43337 RAR
88 STOCK1N‐55604 RAR
89 STOCK1N‐42722 RAR
90 STOCK1N‐24462 RAR
91 STOCK1N‐16139 RAR
92 STOCK1N‐15902 RAR
93 STOCK1N‐23698 RAR
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94 STOCK1N‐22989 RAR
95 STOCK1N‐24428 RAR
96 STOCK1N‐16066 RAR
97 STOCK1N‐16133 RAR
98 STOCK1N‐16074 RAR
99 STOCK1N‐24719 RAR
100 STOCK1N‐24143 RAR
101 STOCK1N‐22983 RAR
102 STOCK1N‐15978 RAR
103 STOCK1N‐16045 RAR
104 STOCK1N‐15956 RAR
105 STOCK1N‐60636 RAR
106 STOCK1N‐20153 RAR
107 STOCK1N‐18419 RAR
108 STOCK1N‐18346 RAR
109 STOCK1N‐18146 RAR
110 STOCK1N‐52556 RAR
111 STOCK1N‐19596 RAR
112 STOCK1N‐18644 RAR
113 STOCK1N‐21191 RAR
114 STOCK1N‐19150 RAR
115 STOCK1N‐20633 RAR
116 STOCK1N‐18712 RAR
117 STOCK1N‐19966 RAR
118 STOCK1N‐43066 RAR
119 STOCK1N‐46335 RAR
120 STOCK1N‐70189 RAR
121 STOCK1N‐45354 RAR
122 STOCK1N‐41727 RAR
123 STOCK1N‐44160 RAR
124 STOCK1N‐47164 RAR
125 STOCK1N‐42617 GNC
126 STOCK1N‐68145 GNC
127 STOCK1N‐54500 GNC
128 STOCK1N‐67126 GNC
129 STOCK1N‐71298 DNC
130 STOCK1N‐31311 GNC
131 STOCK1N‐52625 GNC
132 STOCK1N‐53959 GNC
133 STOCK1N‐03926 GNC
134 STOCK1N‐69096 GNC
135 STOCK1N‐54241 DNC
136 STOCK1N‐23407 GNC
137 STOCK1N‐24052 RAR
138 STOCK1N‐23387 RAR
139 STOCK1N‐29232 RAR
140 STOCK1N‐28930 RAR
141 STOCK1N‐24697 RAR
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142 STOCK1N‐23553 RAR
143 STOCK1N‐24227 RAR
144 STOCK1N‐23949 RAR
145 STOCK1N‐22652 RAR
146 STOCK1N‐23355 RAR
147 STOCK1N‐22664 RAR
148 STOCK1N‐23842 RAR
149 STOCK1N‐23931 RAR
150 STOCK1N‐22702 RAR
151 STOCK1N‐24439 RAR
152 STOCK1N‐23040 RAR
153 STOCK1N‐29531 RAR
154 STOCK1N‐23573 RAR
155 STOCK1N‐23677 RAR
156 STOCK1N‐23484 RAR
157 STOCK1N‐29279 RAR
158 STOCK1N‐28434 RAR
159 STOCK1N‐24233 RAR
160 STOCK1N‐29099 RAR
161 STOCK1N‐29501 RAR
162 STOCK1N‐24327 RAR
163 STOCK1N‐23542 RAR
164 STOCK1N‐22804 RAR
165 STOCK1N‐23301 RAR
166 STOCK1N‐24768 RAR
167 STOCK1N‐23662 RAR
168 STOCK1N‐24765 RAR
169 STOCK1N‐28774 RAR
170 STOCK1N‐24006 GNC
171 STOCK1N‐49811 GNC
172 STOCK1N‐03225 GNC
173 STOCK1N‐10795 RAR
174 STOCK1N‐01204 RAR
175 STOCK1N‐45544 GNC
176 STOCK1N‐07902 RAR
177 STOCK1N‐30669 RAR
178 STOCK1N‐10062 RAR
179 STOCK1N‐55476 RAR
180 STOCK1N‐08511 RAR
181 STOCK1N‐11569 RAR
182 STOCK1N‐25913 RAR
183 STOCK1N‐02920 DNC
184 STOCK1N‐00374 DNC
185 STOCK1N‐34963 GNC
186 STOCK1N‐16515 GNC
187 STOCK1N‐58824 DNC
188 STOCK1N‐69156 DNC
189 STOCK1N‐48711 RAR
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190 STOCK1N‐16916 DNC
191 STOCK1N‐17002 DNC
192 STOCK1N‐69281 RAR
193 STOCK1N‐54462 RAR
194 STOCK1N‐53052 RAR
195 STOCK1N‐51383 RAR
196 STOCK1N‐50855 RAR
197 STOCK1N‐51705 RAR
198 STOCK1N‐52753 RAR
199 STOCK1N‐48731 DNC
200 STOCK1N‐48793 DNC
201 STOCK1N‐47394 DNC
202 STOCK1N‐47851 DNC
203 STOCK1N‐48774 DNC
204 STOCK1N‐48724 RAR
205 STOCK1N‐48732 DNC
206 STOCK1N‐48122 DNC
207 STOCK1N‐49123 DNC
208 STOCK1N‐48619 DNC
209 STOCK1N‐48644 DNC
210 STOCK1N‐47748 DNC
211 STOCK1N‐49178 DNC
212 STOCK1N‐47530 DNC
213 STOCK1N‐48682 RAR
214 STOCK1N‐49242 RAR
215 STOCK1N‐47727 RAR
216 STOCK1N‐48887 RAR
217 STOCK1N‐49323 RAR
218 STOCK1N‐47619 RAR
219 STOCK1N‐49446 RAR
220 STOCK1N‐48033 RAR
221 STOCK1N‐47665 RAR
222 STOCK1N‐48794 DNC
223 STOCK1N‐47453 DNC
224 STOCK1N‐49121 DNC
225 STOCK1N‐49274 DNC
226 STOCK1N‐49196 DNC
227 STOCK1N‐48985 DNC
228 STOCK1N‐49327 DNC
229 STOCK1N‐47529 DNC
230 STOCK1N‐48943 DNC
231 STOCK1N‐47786 DNC
232 STOCK1N‐48358 DNC
233 STOCK1N‐48195 DNC
234 STOCK1N‐49099 DNC
235 STOCK1N‐48164 DNC
236 STOCK1N‐47877 DNC
237 STOCK1N‐47885 DNC
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238 STOCK1N‐48800 DNC
239 STOCK1N‐48684 DNC
240 STOCK1N‐47657 RAR
241 STOCK1N‐48323 DNC
242 STOCK1N‐47810 DNC
243 STOCK1N‐51495 RAR
244 STOCK1N‐56772 DNC
245 STOCK1N‐50434 DNC
246 STOCK1N‐66345 DNC
247 STOCK1N‐44321 DNC
248 STOCK1N‐69994 GNC
249 STOCK1N‐57765 DNC
250 STOCK1N‐56995 GNC
251 STOCK1N‐62919 DNC
252 STOCK1N‐64263 DNC
253 STOCK1N‐59361 RAR
254 STOCK1N‐61856 RAR
255 STOCK1N‐63076 RAR
256 STOCK1N‐59711 RAR
257 STOCK1N‐61627 RAR
258 STOCK1N‐59481 RAR
259 STOCK1N‐59372 RAR
260 STOCK1N‐63343 RAR
261 STOCK1N‐65892 DNC
262 STOCK1N‐66001 DNC
263 STOCK1N‐65962 DNC
264 STOCK1N‐65813 DNC
265 STOCK1N‐59567 RAR
266 STOCK1N‐59597 RAR
267 STOCK1N‐59760 RAR
268 STOCK1N‐62340 RAR
269 STOCK1N‐60376 RAR
270 STOCK1N‐60669 RAR
271 STOCK1N‐63584 RAR
272 STOCK1N‐60559 RAR
273 STOCK1N‐61917 RAR
274 STOCK1N‐59127 RAR
275 STOCK1N‐67951 GNC
276 STOCK1N‐06778 DNC
277 STOCK1N‐50253 GNC
278 STOCK1N‐12110 RAR
279 STOCK1N‐65687 DNC
280 STOCK1N‐62829 RAR
281 STOCK1N‐62053 RAR
282 STOCK1N‐61538 RAR
283 STOCK1N‐63309 RAR
284 STOCK1N‐59395 RAR
285 STOCK1N‐60563 RAR
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286 STOCK1N‐58990 RAR
287 STOCK1N‐59303 RAR
288 STOCK1N‐61829 RAR
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